Doxazosin GITS versus standard doxazosin in mild to moderate hypertension

International Journal of Cardiology

Volumn 101, Issue 1, 2005, Pages 97-104

  Calvo, Carlos ^a   Gil Extremera, Blas ^b   Gomez Fernández, Pablo ^c   Masramon, Xavier ^d   Pueyo, Carol ^e   Armada, Beatriz ^e  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^b HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^c HOSPITAL DE JEREZ   (Spain)

^d Euroclin   (Spain)

^e PFIZER INC   (United States)

Author keywords

Ambulatory blood pressure; Doxazosin; Gastrointestinal therapeutic system; Hypertension; Serum lipids

Indexed keywords

DOXAZOSIN; PLACEBO;

ABDOMINAL PAIN; ADULT; AGED; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE MONITORING; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED DRUG RELEASE; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DIZZINESS; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; FLU LIKE SYNDROME; HEADACHE; HEART PALPITATION; HUMAN; HYPERTENSION; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA; ORTHOSTATIC HYPOTENSION; PERIPHERAL EDEMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TITRIMETRY; TOOTH PAIN; UPPER RESPIRATORY TRACT INFECTION; XEROSTOMIA;

EID: 18144392264     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2004.07.005     Document Type: Article

References (25)

1. American Heart Association Heart disease and stroke statistics-2003 update 2002 American Heart Association Dallas (TX)
2. A.V. Chobanian, G.L. Bakris, and H.R. Black The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report JAMA 289 2003 2560 2571
3. Guidelines Committee 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension J. Hypertens. 21 2003 1011 1053
4. J.A. Staessen, J.G. Wang, and L. Thijs Cardiovascular protection and blood pressure reduction: a meta-analysis Lancet 358 2001 1305 1315
5. M.J. Brown, and J.E. Dickerson Synergism between alpha 1-blockade and angiotensin converting enzyme inhibition in essential hypertension J. Hypertens. 9 1991 S362 S363 [Suppl.]
6. R.G. Englert, and U. Barlage The addition of doxazosin to the treatment regimen of patients with hypertension not adequately controlled by beta-blockers Am. Heart J. 121 1991 311 316
7. B. Fulton, A. Wagstaff, and E. Sorkin Doxazosin. An update of its clinical pharmacology and therapeutic applications in hypertension and benign prostatic hyperplasia Drugs 49 1995 295 320
8. R.M. Guthrie, and R.L. Siegel A multicenter, community-based study of doxazosin in the treatment of concomitant hypertension and symptomatic benign prostatic hyperplasia: the Hypertension and BPH Intervention Trial (HABIT) Clin. Ther. 21 1999 1732 1748
9. H.R. Black, J.S. Sollins, and J.L. Garofalo The addition of doxazosin to the therapeutic regimen of hypertensive patients inadequately controlled with other antihypertensive medications: a randomized, placebo-controlled study Am. J. Hypertens. 13 2000 468 474
10. S. Nalbantgil, I. Nalbantgil, and R. Onder Clinically additive effect between doxazosin and amlodipine in the treatment of essential hypertension Am. J. Hypertens. 13 2000 921 926
11. R.J. Grimm, J. Flack, and G. Grandits Long-term effects on plasma lipids of diet and drugs to treat hypertension. Treatment of Mild Hypertension Study (TOMHS) Research Group JAMA 275 1996 1549 1556
12. P. Andersson, J. Johansson, C. Berne, and H. Lithell Effects of selective alpha 1 and beta 1-adrenoreceptor blockade on lipoprotein and carbohydrate metabolism in hypertensive subjects, with special emphasis on insulin sensitivity J. Hum. Hypertens. 8 1994 219 226
13. I. Os, and H.P. Stokke Effects of doxazosin in the gastrointestinal therapeutic system formulation versus doxazosin standard and placebo in mild-to-moderate hypertension. Doxazosin Investigators' Study Group J. Cardiovasc. Pharmacol. 33 1999 791 797
14. M. Chung, V. Vashi, J. Puente, M. Sweeney, and P. Meredith Clinical pharmacokinetics of doxazosin in a controlled-release gastrointestinal therapeutic system (GITS) formulation Br. J. Clin. Pharmacol. 48 1999 678 687
15. B. Lemmer, and G. Nold Effect of doxazosin GITS on 24-hour blood pressure profile in patients with stage 1 to stage 2 primary hypertension Blood Press. Monit. 8 2003 119 125
16. J. Vincent, H.L. Elliott, P.A. Meredith, and J.L. Reid Doxazosin, an alpha 1-adrenoceptor antagonist: pharmacokinetics and concentration-effect relationships in man Br. J. Clin. Pharmacol. 15 1983 719 725
17. L.N. Daae, and L. Westlie A 5-year comparison of doxazosin and atenolol in patients with mild-to-moderate hypertension: effects on blood pressure, serum lipids, and coronary heart disease risk Blood Press. 7 1998 39 45
18. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group Diuretic versus alpha-blocker as first-step antihypertensive therapy: final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Hypertension 42 2003 239 246
19. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) JAMA 288 2002 2981 2997
20. B.R. Davis, J.A. Cutler, and D.J. Gordon Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Research Group Am. J. Hypertens. 9 1996 342 360
21. ALLHAT Collaborative Research Group Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) JAMA 283 2000 1967 1975
22. J.I. Meltzer A specialist in clinical hypertension critiques ALLHAT Am. J. Hypertens. 16 2003 416 420
23. S.G. Chrysant The ALLHAT study: results and clinical implications QJM 96 2003 771 773
24. G.T. McInnes ALLHAT: a saga of missed opportunities J. Hum. Hypertens. 17 2003 373 377
25. L. Hansson, A. Zanchetti, and S.G. Carruthers Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group Lancet 351 1998 1755 1762